Ductal Carcinoma In Situ

Meet the patient

A 54-year-old woman attends her routine screening mammogram feeling entirely well — no lump, no discharge, no pain. The films show a tight cluster of pleomorphic microcalcifications tracking along a ductal distribution in the upper-outer quadrant. Stereotactic core biopsy reports ductal carcinoma in situ, low to intermediate grade, ER-positive.[5]

The two questions that will govern her whole pathway are the two examiners love to ask: has it stayed behind the basement membrane? (the biopsy says yes), and how do I stop it becoming the invasive cancer that can kill her? Hold those two questions, and every section below slots into place.[5]

The non-obligate precursor — a cancer that may never invade

DCIS is the archetypal non-obligate precursor — a lesion that can become invasive cancer, but does not have to. That single word, "non-obligate", is the concept that makes DCIS a ward-round favourite and the hinge on which all of modern DCIS management turns. The malignant clone has accumulated enough genetic hits to proliferate autonomously inside the duct, but it has not yet learned to break out.[5]

The morphological ladder it sits on is the one to reproduce verbatim in a viva: normal epithelium, then usual ductal hyperplasia, then atypical ductal hyperplasia (ADH), then DCIS, then invasive ductal carcinoma. The step from ADH to low-grade DCIS is partly just quantitative — extent over 2 mm, or involvement of two complete separate spaces — which is why a small suspicious focus on core biopsy is often "upstaged" to DCIS at excision.[5]

The natural-history numbers come from the biopsy-only era before screening — women biopsied and reported as "intramammary carcinoma" but, by error or choice, never treated. Long-term follow-up of those cohorts (the Nashville/Wellings series) showed that about 30 to 50 percent of untreated low- to intermediate-grade DCIS went on to invasive breast cancer in the same breast over 10 to 20 years, almost always in the same quadrant. The other 50 to 70 percent did not progress, even after decades — progression is probable, not inevitable.[5]

How fast it progresses is grade-dependent, which is why grade is the single most important biological variable on the report. High-grade comedo DCIS can invade within months to a few years; low-grade cribriform or micropapillary DCIS may sit indolently for a lifetime. Every histopathology report on a DCIS specimen must therefore state the nuclear grade, the presence or absence of comedo necrosis, and the architectural pattern.[5]

The molecular biology mirrors the morphology. Low-grade DCIS carries gain of 1q and 16p, loss of 16q, low proliferation, ER positivity, a stable genome, and a slow trajectory. High-grade DCIS shows genomic instability, HER2 amplification in 50 to 70 percent of comedo-type, high Ki-67, p53 mutation, ER negativity in a subset, and PI3K/AKT/mTOR activation — a profile that overlaps heavily with high-grade invasive carcinoma. The decisive event in progression is breach of the basement membrane through upregulation of matrix metalloproteinases, loss of cell adhesion, and epithelial-to-mesenchymal transition; once through, the cells are invasive ductal carcinoma and metastasis becomes possible.[5]

The surgeon's corollary: because DCIS can hide an occult invasive focus, 10 to 20 percent of excision specimens that were DCIS on core biopsy turn out to be invasive carcinoma. That redefines the disease — and is exactly why sentinel lymph node biopsy is done at mastectomy for DCIS (see the axillary-staging rule below).[5]

Etymology for viva gold: carcinoma is from the Greek karkinos, "crab" — the distended ducts with their radiating stromal reaction were thought to look like a crab's legs. In situ is Latin for "in its place" — the cells are malignant but still in their proper compartment, the duct. Both words earn easy marks and frame the whole topic.[5]

How common, and the overdiagnosis question

[1]

Before population screening, DCIS was uncommon — only 1 to 5 percent of breast cancers, usually presenting as a palpable mass or nipple discharge. Organised mammographic screening transformed its epidemiology: DCIS is now about 20 to 25 percent of all newly diagnosed breast cancers in screened populations, and roughly 90 percent are detected radiographically as microcalcifications before they are ever palpable. The mean age at diagnosis is the mid-50s, about a decade younger than invasive breast cancer, because DCIS sits earlier in the carcinogenic cascade.[5]

That same rising incidence fuels the overdiagnosis debate — screening picks up indolent lesions that would never have become clinically apparent in a woman's lifetime, yet many are treated with surgery, radiotherapy, and endocrine therapy of uncertain individual benefit. This tension — real progression risk in some women, overtreatment of others — is the central unsolved problem of modern DCIS management and the rationale for the de-escalation trials COMET, LORD, and LORIS, which are testing active surveillance for very-low-risk, screen-detected disease.[5][6]

Risk factors overlap those for invasive breast cancer and cluster around cumulative lifetime oestrogen exposure: early menarche, late menopause, nulliparity, late age at first full-term pregnancy, postmenopausal obesity (peripheral aromatisation of androgens to oestrogen), combined hormone replacement therapy, and prior atypical ductal hyperplasia (roughly a 4 to 5-fold risk). BRCA1/2 carriers, women with a personal or family history of breast cancer, and dense breast tissue all carry added risk. About 75 percent of DCIS is ER-positive, mirroring the luminal predominance of screen-detected disease — and pointing straight at endocrine therapy.[5]

Mammographic microcalcifications — linear branching means comedo

Mammography is the key imaging modality for DCIS, because of its unique sensitivity for microcalcifications. Recognising their morphology and distribution is an exam favourite, and the morphology tells you the grade before you ever see the histology.[5]

• Fine pleomorphic or granular calcifications — varying size and shape, a "crushed-stone" appearance; typical of low- to intermediate-grade DCIS.
• Fine linear or fine linear-branching ("casting") calcifications — outline the necrotic ducts in a discontinuous linear or branching pattern; highly suspicious for high-grade comedo DCIS and carrying the highest positive predictive value for malignancy of any calcification pattern.[1]

The classic trap: granular calcifications overlap with benign causes (sclerosing adenosis, fibrocystic change, fat necrosis) — so a benign-sounding morphology on a screening film does not mean benign. BI-RADS 4 (suspicious) or 5 (highly suggestive of malignancy) calcifications are biopsied, full stop, regardless of how benign the individual grain looks.[1]

The distribution matters as much as the morphology, in increasing order of suspicion: diffuse, then regional, then grouped or clustered, then linear, then segmental. A segmental or linear (ductal) distribution of pleomorphic calcifications is the most characteristic and most suspicious pattern for DCIS, because it reflects a ductal tree filled by the neoplastic process.[5]

BI-RADS assessment categories (Breast Imaging Reporting and Data System):

• BI-RADS 0 — incomplete, recall for additional imaging.
• BI-RADS 1 or 2 — negative or benign; routine screening.
• BI-RADS 3 — probably benign (under 2 percent malignancy risk); short-interval 6-month follow-up.
• BI-RADS 4 — suspicious; biopsy. Subdivided 4a (low), 4b (moderate), 4c (high) suspicion.
• BI-RADS 5 — highly suggestive of malignancy (over 95 percent); biopsy.
• BI-RADS 6 — known biopsy-proven malignancy.[1]

Ultrasound is complementary rather than primary, because pure in situ disease often produces no mass — it assesses any associated mass, guides biopsy of a solid component, and evaluates the axilla. Breast MRI is more sensitive than mammography for the extent of disease (multifocality, multicentricity, occult invasive focus, chest-wall involvement) and is used selectively before mastectomy or when calcification extent is uncertain; its lower specificity can overestimate extent and drive wider excisions, so it is not routine.[5][6]

Clinical presentation — the asymptomatic screen-detected patient

The defining feature of DCIS in the screening era is that most patients are asymptomatic — the diagnosis is made on imaging, not by the patient or the examining clinician.[5]

• Screen-detected microcalcifications (about 90 percent) — the dominant presentation. Pleomorphic, granular or branching calcifications in a ductal (segmental) distribution on routine mammography, with no palpable abnormality.
• Palpable mass (10 to 15 percent) — in larger or higher-grade lesions, particularly comedo DCIS; a palpable DCIS raises the index of suspicion for an occult invasive component.
• Nipple discharge — rarely, spontaneous unilateral bloodstained or serosanguineous discharge from a single duct when subareolar ducts are involved.
• Paget disease of the nipple — an eczematous, scaling, weeping erosion of the nipple-areolar complex from intraepidermal spread of malignant Paget cells; underlying disease is DCIS in a proportion of cases.
• Incidental — found in a biopsy done for another lesion, or in a mastectomy specimen for invasive cancer.[1]

Clinical breast examination is still essential: inspection in four positions (arms by the side, on hips, raised, leaning forward) for asymmetry, skin or nipple change; and supine palpation of all four quadrants, the central areolar area, the axillary tail, and the regional nodes. In pure DCIS the examination is usually normal — a palpable abnormality or nodal enlargement suggests coexisting invasive disease and mandates full triple assessment.[5]

Classification — grade, necrosis, architecture, receptors

DCIS is classified along four independent axes, and every one of them must appear on the histopathology report because each changes prognosis and treatment: nuclear grade, architectural pattern, presence of comedo necrosis, and hormone receptor (ER/PR/HER2) status. The composite Van Nuys Prognostic Index folds grade, size, margin, and age into a single treatment-guiding score (see below).[5]

Nuclear grade is the single most reproducible and prognostically important histological feature, assessed by comparing the DCIS cell nuclei with normal ductal epithelial nuclei.[1]

[1]

Comedo necrosis — cheese-like eosinophilic debris in the centre of a duct involved by high-grade DCIS — is a marker of aggressive biology. Comedo-type DCIS shows HER2 overexpression in 50 to 70 percent, a high Ki-67, frequent p53 mutation, the highest rate of local recurrence and progression to invasion, and characteristically produces linear, branching (casting) microcalcifications that map out the necrotic ducts. Non-comedo patterns (cribriform, micropapillary, solid, papillary) are generally lower grade, more often ER-positive, and carry a better prognosis.[5]

Architectural patterns:[1]

[1]

Mixed patterns are common, and micropapillary DCIS deserves a flag: it tends to be extensive and multicentric, involving more of the ductal tree than its apparent mammographic extent, which can push management toward mastectomy. When several patterns coexist, the highest grade present determines the overall grade assignment.[1]

The Van Nuys ladder — 4 to 6, 7 to 9, 10 to 12

The Van Nuys Prognostic Index (VNPI), developed by Silverstein and colleagues, is the classic composite tool that integrates the strongest predictors of local recurrence into one score that guides treatment intensity. The USC extension adds patient age, giving the USC-VNPI — four factors, each scored 1 to 3, total 4 to 12.[5]

[1] [1]

The number rule to memorise is the three-rung management ladder from the classical Silverstein thresholds:[1]

• Score 4 to 6 (low risk): excision alone may be sufficient — the recurrence rate is low enough that the marginal benefit of radiotherapy is debated.
• Score 7 to 9 (intermediate): excision plus whole-breast radiotherapy; add endocrine therapy if ER-positive.
• Score 10 to 12 (high risk): mastectomy recommended — these lesions are not safely conservable, and radiotherapy is not given after mastectomy for DCIS.[1]

The VNPI is a guide, not a rule. Modern practice leans on multidisciplinary team discussion and shared decision-making, and the SSO/ASTRO/ASCO consensus fixes the operative number that actually governs conservation: a 2 mm margin is adequate for DCIS treated with whole-breast radiotherapy. The VNPI survives as a high-yield exam concept because it crystallises the four determinants of local recurrence into one memorable tool.[5][6]

Like invasive breast cancer, DCIS can also be sorted by receptor status, which guides endocrine therapy and reflects biology:[1]

[1]

About 75 percent of DCIS is ER-positive — the direct rationale for offering tamoxifen (or anastrozole in postmenopausal women) as adjuvant endocrine prevention.[2][4]

Investigations — stereotactic core is the gold standard

The diagnosis of DCIS is made by image-guided needle biopsy of the suspicious calcifications, confirmed histologically, then mapped to plan surgery. The tissue-sampling method of choice is stereotactic core biopsy.[5]

[1]

DCIS is not LCIS — the differential that changes everything

DCIS enters the differential at two points: the radiological differential of suspicious microcalcifications, and the histological differential of an intraductal epithelial proliferation. Both are exam-rich.[5]

[5]

The histological boundary between ADH and low-grade DCIS is the single most common and most important boundary problem in breast pathology. The practical rule for the surgeon: ADH on a core biopsy mandates surgical excision, because a substantial minority harbour unsampled DCIS or invasion.[5]

[5]

The classic trap: DCIS is not LCIS. DCIS is a precursor lesion to be excised; LCIS is a bilateral risk marker managed by surveillance and endocrine prevention, not surgery. Confusing the two in a viva — or in theatre — is the single most damaging error a candidate can make on this topic.[5]

Management — the MDT sets the plan

DCIS is not a surgical emergency. After histological confirmation the case goes to a multidisciplinary team (MDT) meeting — breast surgeon, radiation oncologist, medical oncologist, radiologist, pathologist, breast-care nurse — where extent and receptor status are confirmed and a tailored locoregional and endocrine plan is agreed with the patient. The twin goals are to prevent progression to invasive carcinoma and local recurrence while minimising overtreatment of lesions that may never have progressed.[5][6]

[1]

The decision balances patient factors — age, comorbidity, life expectancy, breast size relative to DCIS extent, preference for conservation versus mastectomy, contraindications to radiotherapy (pregnancy, prior chest irradiation, active connective-tissue disease), and BRCA status — against tumour factors: size, nuclear grade, comedo necrosis, margin status, multifocality or multicentricity, ER status, and extent of calcifications. Young age (under 40) and high nuclear grade are the strongest risk factors for local recurrence after breast-conserving therapy.[5]

[1] [1]

Surgery — clear margins, conserve where you can

Breast-conserving surgery (BCS) — also called wide local excision (WLE), lumpectomy, or partial mastectomy — removes the DCIS with a rim of surrounding normal breast tissue while preserving the breast shape. Combined with whole-breast radiotherapy it is breast-conserving therapy (BCT), the standard of care for most unifocal, conservable DCIS.[1]

Operative technique, in the order it happens in theatre:[1]

• The skin incision is placed to be cosmetically favourable — usually circumareolar, periareolar, or a curved incision following Langer's lines directly over the lesion — and planned so it could sit inside a future mastectomy flap if needed. Avoid radial incisions where possible.
• The DCIS is excised en bloc with a surrounding cuff of normal tissue, guided by the preoperative imaging and, where used, a localisation wire, radioactive seed (RSL), or magnetic or reflective marker placed under ultrasound or stereotactic guidance.
• A specimen radiograph of the excised tissue is performed intra-operatively (when calcifications are targeted) to confirm the microcalcifications are removed and to orient the specimen for margin assessment.
• The specimen is inked (or strategically clipped) in the pathology laboratory so the six margins — superior, inferior, medial, lateral, anterior, posterior — can be individually measured.
• The cavity is usually not closed by mobilising tissue flaps in a simple lumpectomy; careful glandular re-approximation preserves cosmesis.[1]

Margin status is the single strongest modifiable predictor of local recurrence after BCS for DCIS. The 2016 SSO/ASTRO/ASCO consensus guideline established that a margin of at least 2 mm is adequate for DCIS treated with whole-breast radiotherapy — wider margins do not meaningfully reduce recurrence, while positive or close margins (under 2 mm) significantly increase it. Positive margins mandate re-excision to at least 2 mm; if clear margins cannot be obtained, mastectomy is recommended.[5][6]

When the volume that must be excised to clear the DCIS threatens the cosmetic outcome, oncoplastic breast surgery combines oncological resection with plastic-surgical reconstruction of the defect in the same operation, allowing wider, safer margins while preserving or improving breast shape.[1]

• Volume displacement (level I or II oncoplasty): local glandular and dermoglandular flaps are advanced to fill the defect — suitable for excisions up to about 20 to 50 percent of breast volume. Level I covers up to 20 percent; level II (therapeutic mammoplasty, batwing, round-block, J-mammoplasty, Grisotti for central or subareolar lesions) covers 20 to 50 percent.
• Volume replacement: distant or regional tissue — most commonly the latissimus dorsi miniflap, less often an intercostal artery perforator flap — is transferred to fill a partial defect, particularly in small breasts where displacement is impossible.
• Bilateral symmetrisation: contralateral reduction or mastopexy to match the operated breast after a large therapeutic mammoplasty.[1]

Oncoplastic resection earns its place for extensive but unifocal or segmental DCIS that would otherwise need mastectomy, for central subareolar DCIS (where a Grisotti or round-block preserves the nipple), and in small breasts. It demands careful preoperative planning of imaging extent and incision design, and often a two-team surgical-plus-reconstructive approach.[5][6]

Mastectomy removes essentially all breast glandular tissue and is recommended when the DCIS is large (over about 4 cm), multicentric (in more than one quadrant), cannot be cleared with acceptable margins by BCS, when radiotherapy is contraindicated, or by patient choice. Because recurrence risk after a properly performed mastectomy for DCIS is under 2 percent, radiotherapy is NOT given after mastectomy for DCIS — the mastectomy effectively cures the local disease.[5]

The four mastectomy types to name in a viva:[1]

• Total (simple) mastectomy — removal of the entire breast parenchyma, nipple-areola complex, and a small ellipse of overlying skin; the standard oncological operation.
• Skin-sparing mastectomy — parenchyma and nipple-areola complex removed through a periareolar or reduced incision, preserving the native skin envelope for immediate reconstruction; oncologically equivalent to total mastectomy for DCIS.
• Nipple-sparing (subcutaneous) mastectomy — the entire skin envelope including the nipple-areola complex is preserved, with parenchyma removed through an inframammary, periareolar, or lateral incision; reserved for selected, carefully counselled patients having immediate reconstruction, and generally avoided when DCIS involves the subareolar ducts or is extensive.
• Risk-reducing (prophylactic) mastectomy — bilateral mastectomy in a BRCA1/2 carrier or woman at very high genetic risk; reduces breast cancer risk by about 90 to 95 percent.[1]

Immediate or delayed reconstruction — implant, tissue-expander-to-implant, or autologous flap (DIEP, TRAM, or latissimus dorsi) — should be discussed with every woman facing mastectomy; it does not compromise oncological control in DCIS. Because 10 to 20 percent of mastectomy specimens harbour occult invasion, sentinel lymph node biopsy is performed at the time of mastectomy for DCIS.[5]

Folding the surgical options into the VNPI gives a clean treatment algorithm:[5]

[1]

Radiotherapy halves recurrence — NSABP B-17

Whole-breast radiotherapy after breast-conserving surgery roughly halves the risk of ipsilateral local recurrence — both recurrent DCIS and subsequent invasive cancer. The benefit was established by the landmark NSABP B-17 and UK/ANZ DCIS randomised trials and sustained at long-term follow-up.[1][3]

The regimen details that earn marks:[1]

• Dose and fractionation: the conventional regimen is 50 Gy in 25 fractions over 5 weeks to the whole breast. A hypofractionated regimen (40 Gy in 15 fractions over 3 weeks, or 42.5 Gy in 16 fractions) is now widely preferred — at least as effective and cosmetically acceptable, with greater patient convenience.
• Tumour-bed boost: an additional 10 to 16 Gy (commonly 10 Gy in 4 fractions or 16 Gy in 8 fractions) is delivered to the excision cavity for high-grade DCIS and in younger women (under 45 to 50), who carry the highest recurrence risk.
• Magnitude of benefit: radiotherapy reduces the 10-year local recurrence rate by about half — an absolute risk reduction of roughly 10 to 15 percent at 10 years — with the benefit sustained long-term.
• Side effects: acute skin erythema and desquamation, fatigue, breast oedema; late fibrosis, telangiectasia, a small risk of cardiac toxicity (greater for left-sided treatment, minimised by deep-inspiration breath-hold and intensity-modulated techniques), pneumonitis, and a very small long-term excess of secondary angiosarcoma in the irradiated field.[1]

[1]

Accelerated partial breast irradiation (APBI) delivers radiotherapy to the tumour bed only (with a margin) rather than the whole breast, over 1 week or less, via interstitial or intracavitary brachytherapy (for example, a balloon catheter device) or external-beam (3D-conformal or intensity-modulated) techniques. APBI is an option for a highly selected low-risk subgroup — older women (over 50 to 60) with small (under 2 to 2.5 cm), low- to intermediate-grade, ER-positive DCIS excised with widely clear margins. It is not standard for higher-risk DCIS, and several trials continue to define its safe niche. Radiotherapy is not given after mastectomy for DCIS.[5][6]

Endocrine therapy — TAKE by menopausal status

For ER-positive DCIS (about 75 percent of cases), adjuvant endocrine therapy reduces both ipsilateral and contralateral breast events. It is offered in addition to surgery with or without radiotherapy, and its benefit must be weighed against its side effects in the shared-decision context — particularly because DCIS itself is not life-threatening.[2][3][4]

Tamoxifen, a selective oestrogen receptor modulator (SERM), is the standard endocrine agent for DCIS and can be used in women of any menopausal status. In NSABP B-24, 1,804 women with DCIS treated by lumpectomy plus radiotherapy were randomised to tamoxifen 20 mg daily versus placebo for 5 years: tamoxifen reduced all breast-cancer events at 5 years (8.2 percent versus 13.4 percent), with the benefit concentrated in ER-positive DCIS, reducing both ipsilateral and contralateral breast cancer by roughly 30 percent. The dose is 20 mg orally once daily for 5 years.[2]

The side-effect profile every candidate must reproduce:[1]

• Vasomotor: hot flushes (about 30 percent) and night sweats — the commonest and most compliance-limiting.
• Thromboembolic: roughly a 2 to 3-fold increased risk of deep vein thrombosis and pulmonary embolism — avoid in women with prior VTE.
• Endometrial: a 2 to 3-fold increased risk of endometrial cancer, hyperplasia, and polyps (oestrogen-agonist effect on the endometrium) — investigate any postmenopausal bleeding.
• Ocular: cataracts, rare retinopathy.
• Hepatic: fatty liver, mildly elevated transaminases.
• Gynaecological or menstrual: vaginal discharge, menstrual irregularity.[1]

For postmenopausal women, the aromatase inhibitor anastrozole is an alternative with a different side-effect profile. In IBIS-II DCIS, postmenopausal women with locally excised DCIS were randomised to anastrozole 1 mg daily versus tamoxifen 20 mg daily for 5 years: there was no significant difference in overall recurrence (a non-significant trend favouring anastrozole), but the toxicity profiles differed — tamoxifen caused more gynaecological symptoms and venous thromboembolism, while anastrozole caused more musculoskeletal symptoms, fractures (osteoporosis), and vasomotor flushes. The dose is anastrozole 1 mg orally once daily for 5 years (postmenopausal only).[4]

The aromatase-inhibitor side-effect set, and how it differs from tamoxifen:[4]

• Bone: osteoporosis and fractures — monitor with baseline and periodic DEXA.
• Musculoskeletal: arthralgia and myalgia.
• Vasomotor: hot flushes (less than with tamoxifen).
• No thromboembolism or endometrial cancer — unlike tamoxifen.[4]

[1] [1]

The classic trap: an aromatase inhibitor given to a premenopausal woman without ovarian suppression does not lower her oestrogen — it can paradoxically raise it by driving gonadotropin release. Anastrozole is a postmenopausal-only drug in DCIS; give tamoxifen to the premenopausal woman, and never give tamoxifen to a woman with prior VTE.[1]

The trials that built DCIS management

Modern DCIS management rests on four landmark randomised trials, and an examiner expects you to name each and say what it changed.[5]

[1] [1] [2] [3] [1] [4]

The SSO/ASTRO/ASCO margin consensus (2016) then fixed the operative number that governs conservation: 2 mm is an adequate margin for DCIS treated with whole-breast radiotherapy, ending the debate over wider margins and reducing re-excision rates. The de-escalation trials COMET, LORD, and LORIS are now testing whether active surveillance is safe for the lowest-risk subgroup.[6]

Surveillance — watch for the invasive recurrence

The aim of follow-up is early detection of ipsilateral local recurrence, a contralateral new primary, and — if a recurrence is invasive — timely salvage. DCIS itself is highly curable, but an invasive recurrence is the event that threatens survival, which is why surveillance matters.[5][6]

The standard surveillance schedule, after BCS plus RT or after mastectomy:[1]

• Clinical breast and nodal examination every 6 to 12 months for the first 2 to 3 years, then annually. Most recurrences occur within the first 5 to 10 years.
• Annual mammography of the conserved and contralateral breast, beginning 6 to 12 months after completion of radiotherapy. After bilateral mastectomy, mammography is not routine (chest-wall clinical examination suffices); mammography of a preserved contralateral breast continues.
• No routine blood tests, tumour markers, chest imaging, bone scans, or CT in the asymptomatic patient — these do not improve survival in DCIS and are not recommended by ASCO or NCCN. Imaging is directed by symptoms.
• Endocrine-therapy adherence for the full 5 years, with baseline and periodic DEXA monitoring on an aromatase inhibitor, and prompt investigation of any vaginal bleeding on tamoxifen (endometrial cancer).
• Psychological support and breast-awareness counselling, addressing the anxiety of a "cancer" diagnosis for a disease that is rarely life-threatening, and supporting body-image recovery after surgery and radiotherapy.[1]

Most local recurrences after BCS plus RT occur in or near the original tumour bed. About half of all recurrences are invasive ductal carcinoma (and half recurrent DCIS) — it is the invasive recurrences that carry mortality risk, which is why surveillance is non-negotiable.[5]

When recurrence happens, management follows the type of recurrence, its site, and the prior treatment:[5]

• Recurrent DCIS after breast-conserving therapy: repeat wide local excision to clear margins; because a second breast-conserving attempt in an irradiated breast is cosmetically and oncologically problematic, completion mastectomy is often the preferred salvage, and re-irradiation is rarely feasible.
• Invasive recurrence (about half of all recurrences): treat as a new primary invasive breast cancer — usually mastectomy, sentinel lymph node biopsy for axillary staging (lymphatic mapping usually still possible), and full receptor staging with systemic therapy by subtype.
• Recurrence after mastectomy is uncommon (under 2 percent) and is managed by local excision of the chest-wall recurrence, with radiotherapy if not previously given, and systemic therapy by subtype.
• Contralateral new primary is treated as a new breast cancer in its own right — its own triple assessment, staging, and subtype-directed therapy.[1]

The single most important prognostic point: a recurrence that is invasive is what can kill the patient, whereas recurrent DCIS is again a local problem. That is the biological justification for aggressive prevention of recurrence in the first place — clear margins, radiotherapy, and endocrine therapy.[5][6]

Special populations

Young women (under 40) have a higher recurrence rate after breast-conserving therapy, more often harbour occult invasion and BRCA mutations, and warrant careful extent-of-disease imaging (often MRI); mastectomy is more frequently chosen. Genetic testing (BRCA1/2 and multigene panel) should be offered to young women with DCIS and a suggestive personal or family history.[1]

BRCA1/2 carriers with DCIS receive standard locoregional therapy but should be counselled about risk-reducing bilateral mastectomy and bilateral salpingo-oophorectomy, enhanced surveillance (annual breast MRI), and the value of endocrine prevention; genetic testing is offered based on risk-prediction models and family history.[5]

Pregnancy-associated DCIS is rare. Mammography with abdominal shielding is safe; gadolinium MRI is avoided in the first trimester. Surgery is safe in any trimester; radiotherapy is deferred until after delivery; tamoxifen is absolutely contraindicated (teratogenic). Decisions are individualised within the MDT.[1]

Older and frail patients with low-grade, ER-positive DCIS may be excellent candidates for endocrine therapy with minimal surgery, or in some, active surveillance, weighing the competing risks of comorbidity against the often-indolent natural history. Under-treating highly curable disease in older women who could tolerate standard therapy is equally a pitfall.[5][6]

Regional deltas

Complications of treatment

Complications of surgery include seroma (the commonest, managed by aspiration), haematoma, wound infection, poor cosmetic outcome (especially after large or re-excision lumpectomies), and — after axillary surgery for occult invasion — lymphoedema (5 to 8 percent after sentinel node biopsy), shoulder stiffness, chronic pain, and intercostobrachial nerve sensory loss. Immediate reconstruction carries its own set: implant capsular contracture, flap loss, donor-site morbidity.[5]

Complications of radiotherapy include acute skin reactions and fatigue, and late fibrosis, breast shrinkage and asymmetry, cardiac toxicity (minimised with modern breath-hold and intensity-modulated techniques), pneumonitis, brachial plexopathy, and a small long-term excess of secondary angiosarcoma in the irradiated field — classically presenting years later as a violaceous skin plaque.[5]

Complications of endocrine therapy are the tamoxifen set (VTE, endometrial cancer, hot flushes) and the aromatase-inhibitor set (osteoporosis, fractures, arthralgia) detailed above.[1]

The recurring pitfalls every candidate must name:[1]

• Treating DCIS with the intensity of invasive cancer in a low-risk, elderly woman with indolent disease — overdiagnosis and overtreatment.
• Failing to achieve or re-excise a margin under 2 mm after BCS — the single strongest correctable recurrence risk.
• Omitting radiotherapy after breast-conserving surgery for higher-risk DCIS without a considered low-risk justification.
• Giving tamoxifen to a premenopausal woman with prior VTE, or an aromatase inhibitor to a premenopausal woman without ovarian suppression.
• Routine sentinel node biopsy for pure DCIS treated by BCS — not indicated; reserve for mastectomy or high suspicion of invasion.
• Confusing DCIS with LCIS — DCIS is treated as a precursor; LCIS is a risk marker managed by surveillance and prevention, not surgery.
• Mislabelling an ADH core biopsy as benign without surgical excision — ADH on core must be excised (about 15 to 30 percent upstage to DCIS or invasion).
• Forgetting contralateral and endocrine-prevention considerations even after mastectomy.[1]

Prognosis and disposition

DCIS is highly curable. Breast cancer-specific survival is approximately 97 to 99 percent at 10 years, and overall mortality from DCIS itself is very low; the small excess mortality in DCIS cohorts is driven by the minority who develop invasive recurrence. After mastectomy, local recurrence is under 2 percent. After breast-conserving therapy (BCS plus RT), local recurrence is roughly 10 to 15 percent at 10 years, with about half invasive. Excision alone (selected low-risk cases) carries a higher recurrence rate of about 20 to 30 percent at 10 years — the rationale for adding radiotherapy in all but the lowest-risk cases.[1][5]

Risk factors for local recurrence after breast-conserving therapy:[1]

• Positive or close margins (under 2 mm) — the strongest modifiable factor.
• Young age (under 40) — an independent risk factor.
• High nuclear grade and comedo necrosis.
• Large size or extensive disease.
• Omission of radiotherapy, and (to a lesser degree) omission of endocrine therapy for ER-positive disease.
• Positive family history or BRCA mutation.[1]

Disposition is to a multidisciplinary breast cancer follow-up programme with annual mammography and clinical examination, endocrine-therapy adherence and bone-density monitoring where relevant, and psychological and rehabilitation support. The contemporary shift is toward risk-adapted de-escalation — identifying the very-low-risk subgroup for whom excision alone or even active surveillance is appropriate, while continuing full therapy for higher-risk disease.[5][6]

The mantra, and the mnemonic

[1] [2] [4]

The mantra: clear margins, add radiotherapy, tamoxifen if ER-positive, watch the axilla only at mastectomy.[1][2]

Ward-round test — three stems, thirty seconds each

Stem 1 — the asymptomatic woman with calcifications (answer)

A 54-year-old woman is recalled after screening mammography shows a 3 cm cluster of fine linear branching microcalcifications in a segmental distribution in the upper-outer quadrant. She has no lump and no symptoms. What is the diagnosis to exclude, and what is your next investigation? Model: The morphology and distribution (fine linear branching, segmental) are highly suggestive of high-grade comedo DCIS — linear branching calcifications map out necrotic ducts and carry the highest positive predictive value for malignancy. The next investigation is stereotactic core needle biopsy of the calcifications (a vacuum-assisted 9- to 11-gauge device), with ER/PR/HER2 sent on the core. Do not be reassured by her asymptomatic presentation — about 90 percent of DCIS is detected this way.[5]

Stem 2 — the 1 mm margin after breast-conserving surgery (answer)

A 48-year-old woman has wide local excision for intermediate-grade, ER-positive DCIS. The histopathology report shows DCIS reaching to within 1 mm of the inferior margin. What is your next step, and why? Model: A margin under 2 mm is not adequate for breast-conserving therapy (SSO/ASTRO/ASCO 2016) — margin status is the single strongest modifiable predictor of local recurrence. She needs re-excision to achieve at least 2 mm; if clear margins cannot be obtained, the operation converts to mastectomy. Once margins are clear she proceeds to whole-breast radiotherapy (which halves recurrence, NSABP B-17) and tamoxifen 20 mg once daily for 5 years because she is ER-positive (NSABP B-24). The axilla is not staged — pure DCIS cannot metastasise, and she had breast-conserving surgery, not mastectomy.[5][6]

Stem 3 — endocrine therapy in a 62-year-old postmenopausal woman (answer)

A 62-year-old postmenopausal woman has completed breast-conserving surgery and radiotherapy for ER-positive DCIS. She had a deep vein thrombosis two years ago. Which endocrine agent, and why not the other? Model: Anastrozole 1 mg once daily for 5 years is the right choice here. Tamoxifen is contraindicated because her prior VTE makes its 2 to 3-fold thromboembolic risk unacceptable — and because an aromatase inhibitor, unlike tamoxifen, carries no increased VTE or endometrial-cancer risk. IBIS-II DCIS showed anastrozole and tamoxifen have equivalent efficacy in postmenopausal DCIS with different toxicity profiles; in this woman the toxicity profile decisively favours anastrozole. Add baseline and periodic DEXA monitoring, because aromatase inhibitors cause osteoporosis and fractures. Never give an aromatase inhibitor to a premenopausal woman without ovarian suppression — but she is postmenopausal, so this is safe.[4]

References

1. [1]Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17 J Clin Oncol, 1998.PMID 9469327
2. [2]Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet, 1999.PMID 10376613
3. [3]Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet, 2003.PMID 12867108
4. [4]Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial Lancet, 2016.PMID 26686313
5. [5]Nash AL, Hwang ES. The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment Ann Surg Oncol, 2023.PMID 37024766
6. [6]Buchheit JT, Schacht D, Kulkarni SA Update on Management of Ductal Carcinoma in Situ Clin Breast Cancer, 2024.PMID 38216382